Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
In mid-September, Novo Nordisk inked a pair of deals worth a total of more than $1.1 billion in research and development (R&D) costs, payments, milestone fees, and royalties, with the explicit aim of bolstering its cardiometabolic disease therapy pipeline via as-yet-unexplored therapeutic modalities.
The healthcare company's pivot into a new set of technologies will have many implications for the stock.
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
Robert F. Kennedy Jr. criticized Ozempic and Danish pharmaceutical company Novo Nordisk, arguing that fixing the food supply ...
(Reuters) -German drug and development company Evotec has entered into a technology development partnership with Novo Nordisk ...
Shares of Novo Nordisk (NVO) slipped on Friday following a note from JPMorgan's Richard Vosser. Vosser warned that the pharmaceutical giant's third quarter results could show a slowing in sales of ...
Novo Nordisk has earnt yet another dressing down from the PMCPA. The U.K. | Novo Nordisk has earnt yet another dressing down ...
The obesity-drug hype that fueled huge gains in Novo Nordisk A/S looks to be running out of steam. Novo shares fell as much as 4.6% to a seven-month low on Friday after a JPMorgan Chase & Co ...
European health-care stocks are set to snap their longest winning streak since March 2010, dragged down by concerns over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback